1. Berger Montague investigates securities fraud claims against Spectrum Pharmaceuticals. 2. The lawsuit alleges misleading statements regarding a clinical trial. 3. Spectrum shares were delisted after merging with Assertio Holdings. 4. Investors have until September 24, 2025, to act as lead plaintiff.
The ongoing lawsuit and delisting indicate potential instability and risk for investors, possibly affecting ASRT negatively. Historical precedents show mergers involving legal issues often lead to stock price declines, as seen with prior cases like Valeant Pharmaceuticals.
The investigation into Spectrum’s fraud and its relation to ASRT through the merger could cause negative sentiment amongst investors, driving ASRT's stock down. Investor concerns about legal ramifications may lead to increased selling pressure.
The immediate implications from the lawsuit and delisting will likely influence ASRT's stock price in the short-term. Legal actions typically unfold rapidly, impacting market perceptions quickly.
PHILADELPHIA, Aug. 25, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period").
Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.
Spectrum is a biopharmaceutical company focused on oncology treatments.
The class action lawsuit alleges that Spectrum made false or misleading statements to investors regarding its Pinnacle Study, a clinical trial involving poziotinib, a drug intended to treat certain lung cancer patients.
Spectrum shares were delisted following the Company's merger with Assertio Holdings, Inc. (NASDAQ:ASRT).
If you are a Spectrum investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
About Berger Montague
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com
Caitlin Adorni
Berger Montague
(267) 764-4865
cadorni@bergermontague.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nasdaq-sppi-deadline-reminder-berger-montague-reminds-spectrum-pharmaceuticals-inc-nasdaq-sppi-investors-of-important-class-action-lawsuit-deadline-302537284.html
SOURCE Berger Montague